看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。 L, w# P8 b J1 J" W
) _- Z- W! |& R3 J! F3 B3 b; R4 f1 Z2 G$ Y, j/ c6 L$ q9 f. P d
Currently available feasibility data for possible combination strategies.
0 d8 s! x) d; e$ u————————————————————————————————# w) T. k& j! k* e' j6 L& v
Combination Feasibility according to preliminary data # d# G ~; {0 h# m& n9 | R7 I
——————————————————————————————————
6 c2 H$ r5 O z3 a4 wBevacizumab + sorafenib Yes, reduced dose & S, t4 Y1 q) z- g6 z
Bevacizumab + sunitinib† No + p, ~: ?1 L; E ~8 w/ x
Bevacizumab + temsirolimus Yes
2 @8 F; [9 Q8 B1 A7 a4 sBevacizumab + everolimus Yes - u$ C0 o0 X) B# u& p
Sorafenib + sunitinib ? + s' M* h+ R3 y6 `. R
Sorafenib + temsirolimus Yes, reduced dose ' b/ a- f. F* A" C5 L
Sorafenib + everolimus Yes, reduced dose 8 o& e% S! i1 J& [/ G5 ~
Sunitinib + temsirolimus† No
2 J7 w* U, j; _' gSunitinib + everolimus ?
U# E E, ?2 v- y' F2 E) m$ ZTemsirolimus + everolimus ?
# P( f2 ~( I3 G% |6 U* x9 R+ Y( e————————————————————
5 P- k4 v) `/ n†Led to US FDA warning.
3 b) F- v6 u, b9 d3 @1 M?: As yet unattempted combination.
$ o0 E1 Z3 C4 a3 D |